AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05672628 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oculus VR
Description: During the first visit, the Oculus headset will be placed on the stroke survivor's head and demonstrate how to use the headset. participant will be then allowed to play a game using the hand controllers for up to 30 minutes. Finally, a copy of exercises for their home rehabilitation program will be provided. During the next rehabilitation visits, a trained research assistant will guide the stroke survivor with using the gaming headset. The session will be stopped every 20 minutes to make sure that the stroke survivor is feeling well and to give them a break. The stroke survivor may stop the session at any time. This session will last for an hour.
Study NCT05286736 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Neuroimaging
Description: This project will use neuroimaging (7T MRI: structural, diffusion and rest-state functional MRI) and non-invasive brain stimulation (TMS: PAS. SAI) techniques to quantify structural and functional changes in brain function.
Study NCT05286736 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative assessments
Description: Quantitative assessments of motor function (gait, gait initiation, reactive balance, bradykinesia, repetitive alternating movements, rigidity, stop-signal reaction time), and neuropsychological function
Study NCT05879523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-1893
Description: subcutaneous, single dose, multiple doses
Study NCT05879523 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous, single dose, multiple doses
Study NCT05029271 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: InPen with Guardian 4 System
Description: Subjects will receive the InPen™ and InPen™ Diabetes Management App combined with the Guardian™ 4 system.
Study NCT06089109 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The Big 3
Description: Our research team has developed an online, interactive learning management system (LMS) training. This training seeks to provide helping professionals with information and resources to identify, intervene, and prevent maternal injuries from interpersonal violence, substance use/disorder (IPV and SU/D). This training will provide healthcare professionals with the knowledge, skills, and efficacy to intervene and build capacity for prevention of maternal injuries and death due to violence.
Study NCT06089109 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Implementation and Effectiveness of VIP Corps Training
Description: Implement and evaluate the effectiveness of VIP Corps training aimed at students enrolled in helping professions in their last program year. intervention efficacy to change in students' knowledge, attitudes, and practices of intimate partner violence (IPV) screening, detection, and referrals; participant practices will be the primary, longer-term outcome; while changes in knowledge and attitudes will be short-term outcomes. Secondary outcomes will include changes in detecting symptoms of a) SU/D and b) depression and/or anxiety and providing appropriate resources.
Study NCT06142643 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermal Filler Device
Description: Injection of the device by investigators according to the IFU
Study NCT06152614 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Description: Enhanced Usual Care (EUC) includes 5 weeks of hypertension classes.
Study NCT06152614 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food Delivery and Cooking PLUS Aerobic Training (FoRKS+)
Description: Food Delivery and Cooking PLUS Aerobic Training (FoRKS+) includes 5 weeks of hypertension classes followed by 11 weeks of home-delivered Mediterranean-style ingredient kits and virtual cooking classes, and an additional 12 weeks of aerobic exercise.
Study NCT06214936 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Benchtop Incubator
Description: half of the mature oocytes will be placed in the benchtop incubator and after ICSI the resulting inseminated oocytes and subsequent embryos will remain in the benchtop incubator for the remainder of embryo culture
Study NCT06214936 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Box Incubator
Description: half of the mature oocytes will be placed in the benchtop incubator and after ICSI the resulting inseminated oocytes and subsequent embryos will remain in the box incubator for the remainder of embryo culture
Study NCT06647290 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy
Description: Application of a negative wound pressure therapy dressing to the wound post laparotomy
Study NCT06647290 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Negative Pressure Wound Therapy
Description: Application of a negative wound pressure therapy dressing to the wound post laparotomy
Study NCT06647329 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T Therapy
Description: CAR-T Technology for the Treatment of Recurrent/Refractory Malignant Hematological Lymphomas
Study NCT06646380 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multicomponent Training
Description: The multicomponent training (MCT) program comprised aerobic, resistance, flexibility, and balance exercises, following recommendations by Carvalho et al. (23). Sessions lasted 50 to 60 minutes, including warm-up, aerobic exercise, resistance training, balance training, and cool-down. Training intensity gradually increased over time. The experimental group will have three 60-minute sessions weekly for 32 weeks, while the control group will not participate in any exercise program, but they will maintain the daily physical activity. Both groups will be evaluated at two time points: initial assessment (M1) at the start of training and final assessment (M2) after 32 weeks
Study NCT06646380 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Maintenance
Description: Participants were instructed to maintain daily life activities regarding physical activity.
Study NCT04655014 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Circuit Training
Description: The High Intensity Circuit Training comprises of 7 full body exercises as per recommendation of ACSM Where the participants shall be given total of 18 sessions of their respective protocol, comprising of 20 minutes, 3 times/ week for duration of six weeks
Study NCT06645639 — intervention group
Intervention type: OTHER
Intervention: Pediatric Integrated Nutrition Pathway for Acute Care Pathway (P-INPAC)
Description: The pediatric working group of Canadian Malnutrition Task Force has developed an evidence-informed algorithm named the Pediatric Integrated Nutrition Pathway for Acute Care (P-INPAC). The P-INPAC outlines a process to improve nutrition care by:~1. implementing nutrition screening at point-of-admission~2. introducing standard care measures to prevent the development of malnutrition in children admitted with normal nutrition status, including standardizing the process of monitoring food intake early and systematically to identify when standard care measures are not sufficient~3. ensuring the moderately and severely malnourished patients receive timely specialized care in the form of a comprehensive assessment and treatment; and~4. ensuring moderately and severely malnourished patients receive adequate post discharge follow-up and nutrition care.~In this pilot study, we will be implementing the first two steps of P-INPAC only (screening and assessment).
Study NCT05250622 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Japanese-translated evidence summaries (Advanced Clinical Evidence report from OrthoEvidence)
Description: Participants will receive emails with the link to Japanese-translated version of evidence summaries.
Study NCT05250622 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: English evidence summaries (Advanced Clinical Evidence report from OrthoEvidence)
Description: Participants will receive emails with the link to English version of evidence summaries.
Study NCT05608096 — intervention group
Intervention type: DEVICE
Intervention: Hemoperfusion
Description: Commercial membrane for extracorporeal blood purification (hemoperfusion)
Study NCT05518383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate
Description: For patients with very limited disease (R1- stage I/II СR), the addition of rituximab might allow the omission of anthracyclines and vincristine without jeopardizing survival rates but reducing acute and long term toxicities. In this treatment arm, it is tested whether the event-free survival is similar to that of the historical control
Study NCT06646393 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin to skin contact
Description: Father-baby skin-to-skin contact was applied within the first hour immediately after the cesarean delivery. During the Father-Baby Skin-to-Skin Contact stage, the newborns were laid face down on their father's bare chest and covered with a blanket.
Study NCT05518383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate, Vincristine
Description: R2: Drug: Rituximab 2 doses of Rituximab (375 mg/m²) before the start of the first chemotherapy cycle, 2 doses of Rituximab before the start of the second chemotherapy cycle
Study NCT05518383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, vincristine
Description: 2 doses of Rituximab (375 mg/m²) before the start of the first chemotherapy cycle, 2 doses of Rituximab before the start of the second
Study NCT05518383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide , Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, Vincristine, Сarboplatine, CCNU/ BCNU, Melphalan, Idarubicin
Description: Rituximab 4 doses of Rituximab (375 mg/m²) before the start of the first chemotherapy cycle, Further
Study NCT06307184 — intervention group
Intervention type: PROCEDURE
Intervention: Natural proliferative phase frozen embryo transfer
Description: When endometrial thickness is above 7 mm, vaginal micronized progesterone will be administered 400mg 12/12h when the dominant follicle is at least 13 mm, serum estradiol (E2) levels are >80 pg/ml, and serum progesterone levels are \<1.5ng/ml. Embryo transfer will be performed on the fifth day of progesterone.
Study NCT05819996 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Environmental educational campaign
Description: Educational campaign will be conducted to promote participation in indoor air testing.
Study NCT05966129 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pharmacogenetic testing
Description: Genetic testing of CYP2D6 and CYP2C19
Study NCT05966129 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic testing
Description: Genetic testing of CYP2D6 and CYP2C19
Study NCT05966129 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical decisions support
Description: Prescribing recommendations to the provider based on the pharmacogenetic testing results
Study NCT05218096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN2050
Description: Oral tablet.
Study NCT05218096 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet.
Study NCT03617445 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FMT oral capsule
Description: FMT oral capsules, single dose of 5 capsules
Study NCT03617445 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Vancomycin
Description: Oral Vancomycin 125 mg capsules every 6 hours for 14 days, followed by 125 mg oral placebo every 12 hours for 7 days, followed by 125 mg oral placebo once daily for 7 days, followed by 125 mg oral placebo every 3 days for 14 days
Study NCT03617445 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FMT oral placebo
Description: Placebo oral capsules, single dose of 5 capsules
Study NCT03617445 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Vancomycin placebo
Description: Placebo oral vancomycin capsules every 6 hours for 14 days, followed by 125 mg oral vancomycin every 12 hours for 7 days, followed by 125 mg oral vancomycin once daily for 7 days, followed by 125 mg oral vancomycin every 3 days for 14 days.
Study NCT05896527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DC-806
Description: DC-806 will be supplied as tablets to be administered orally.
Study NCT05896527 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be supplied as tablets to be administered orally.
Study NCT04978454 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza RG-A/Texas/71/2017 (H3N2) Challenge
Description: RG-A/Texas/71/2017 (H3N2) is an infectious influenza virus and requires handling at BioSafety Level 2. The challenge virus will be administered intranasally in a volume of approximately 0.5 mL per nostril. Intranasal challenge will be carried out using the Intranasal Mucosal Atomization ( MAD Nasa(TM)) Device attached to a 1 mL syringe.
Study NCT04978454 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sucrose phosphate glutamate (SPG) inoculum
Study NCT06428708 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [18F] PSMA-1007 PET/CT
Description: \[18F\] PSMA-1007 PET/CT scan
Study NCT05881148 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbon sprinting spiked-shoes
Description: Trademarked Carbon Spiked-Shoes, from one Trademark only to ensure generalization concerns, is used alternatively with standard carbon-free spiked-shoes, for 8 repetitions of 30m-sprint each, separated by 10 minutes rest each.
Study NCT05881148 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard carbon-free sprinting spiked-shoes
Description: cf
Study NCT06325579 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immersive Virtual Reality for Dysphagia Treatment
Description: Patients wore a VR headset while undergoing their rehabilitation session
Study NCT04799054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TransCon TLR7/8 Agonist
Description: TransCon TLR7/8 Agonist will be administered as an IT injection
Study NCT04799054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered IV
Study NCT05325255 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial release of subscapularis
Description: It is the application of manual pressure over myofascial trigger point that induces ischemia and causes release of trigger points
Study NCT05325255 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Maitland mobilization
Description: It is the type of mobilization technique that uses passive accessory mobilization to reduce pain and stiffness and increasing range of motion
Study NCT05325255 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maitland mobilization
Description: It is the type of mobilization technique that uses passive accessory mobilization to reduce pain and stiffness and increasing range of motion
Study NCT05325255 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching exercises
Description: It is the technique use to increase flexibility and range of motion of short and hypomobile structures
Study NCT05325255 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching exercises
Description: It is the technique use to increase flexibility and range of motion of short and hypomobile structures
Study NCT05325255 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cold pack
Description: It is the application of cold to provide analgesic effects
Study NCT05325255 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold pack
Description: It is the application of cold to provide analgesic effects
Study NCT05529160 — intervention group
Intervention type: DEVICE
Intervention: FERTI LILY Conception Cup
Description: The FERTI-LILY Conception Cup is indicated for over-the-counter (OTC) home use by couples trying to conceive. The FERTI·LILY device OTC contains a cervical cap attached to a stem. The FERTI-LILY Conception Cup is intended to push semen towards the cervix as an aid in conception. It is designed to be inserted vaginally after intercourse and left in place for 20-60 minutes. The device is recommended to be used during the ovulatory phase of the menstrual cycle. It is not to be left in place for longer than six hours. The device may be re-used up to 18 times or over 6 cycles.
Study NCT05922839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Zanubrutinib 160mg, orally, twice daily, for a minimum of 3 months, and for effective patients, continue to use for 2 years after achieving optimal therapeutic effect.
Study NCT06282809 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HistoSonics Edison™ System for the treatment of pancreatic adenocarcinoma using histotripsy
Description: Histotripsy is a non-thermal, mechanical process of focused ultrasound used to mechanically destroy targeted soft tissue.
Study NCT06341621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3-year abemaciclib without chemo
Description: aromatase inhibitors (± ovarian suppression) plus 3-year abemaciclib (100mg bid) without chemotherapy.
Study NCT06341621 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: treatment of physician's choice
Description: treatment of physician's choice including whether to receive chemotherapy, chemotherapy regimen and endocrine therapy regimen.
Study NCT05608304 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Formal mindfulness induction
Description: The formal mindfulness induction will consist of a 10-minute audio recording of a sitting meditation, guiding the participant to consciously and repeatedly bring their attention to their breath and inner experience with nonjudgmental acceptance.
Study NCT05608304 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Informal mindfulness induction
Description: The informal mindfulness induction will consist of on-screen instructions guiding participants through the completion of four routine tasks (washing hands, drinking water, laying down, listening to music) with mindful awareness and acceptance over the course of 10 minutes.
Study NCT05608304 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control task
Description: Participants assigned to the active control condition will be prompted to download a single-page document containing 100 letters, numbers, and symbols, and a grid of 100 boxes. Following along with a guided audio, participants will be instructed to place all of the characters in the grid in a specific order over the course of 10 minutes. A version of this task has been used in previous studies by our team (Carsley \& Heath, 2019; Petrovic et al., 2022) and has been shown not to impact mindfulness levels, and was thus deemed an appropriate neutral attention task for this study.
Study NCT04999644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Full Nicotine Cigarettes
Description: A full nicotine tobacco cigarette that will be smoked by participants
Study NCT04999644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reduced Nicotine Cigarettes
Description: A reduced nicotine tobacco cigarette that will be smoked by participants
Study NCT04999644 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Average Nicotine Expectancy
Description: Participant instructed the cigarette is the same level of nicotine as your usual brand.
Study NCT04999644 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Very Low Nicotine Expectancy
Description: Participant instructed the cigarette is a very low level of nicotine compared to your usual brand.
Study NCT06645860 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SDF+KI+LED Light 20s
Description: After the silver diamine fluoride (SDF) and potassiım iodide (KI) application, 20-second LED light will be applied to the cavity.
Study NCT06645860 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: SDF+KI
Description: Silver diamine fluoride (SDF) and potassium iodide(KI) will be applied.
Study NCT06645860 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SDF+KI
Description: Silver diamine fluoride (SDF) and potassium iodide(KI) will be applied.
Study NCT06645730 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: hypertension
Description: diagnosed with hypertension
Study NCT06645730 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: diabetes
Description: diagnosed with diabetes
Study NCT06645730 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: fatty liver
Description: diagnosed with fatty liver on CT
Study NCT05797116 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: 29-item Dutch survey about the implementation and practice variation of preoperative multidisciplinary team (MDT) meetings for high risk noncardiac surgical patients in the Netherlands.
Study NCT06243185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalpiciclib plus letrozole
Description: Dalpiciclib 150mg qd, d1-21, repeated once every 4 weeks. Letrozole 2.5mg qd, repeated once every 4 weeks.
Study NCT06382714 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: For the intervention group, a museum visit with virtual reality glasses will be applied.
Description: Patients will visit a museum while undergoing hemodialysis with virtual reality glasses for a total of five sessions for intervention group
Study NCT05884463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FAPI
Description: Intravenous injection of one dosage of 18F-FAPI.
Study NCT05884463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FDG
Description: Intravenous injection of one dosage of 18F-FDG.